Advisory Services Network LLC Acquires 2,370 Shares of Eli Lilly and Company $LLY

Advisory Services Network LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% in the 3rd quarter, Holdings Channel.com reports. The firm owned 50,933 shares of the company’s stock after acquiring an additional 2,370 shares during the period. Eli Lilly and Company comprises 0.6% of Advisory Services Network LLC’s holdings, making the stock its 19th biggest position. Advisory Services Network LLC’s holdings in Eli Lilly and Company were worth $38,862,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Kozak & Associates Inc. grew its position in shares of Eli Lilly and Company by 140.0% during the 3rd quarter. Kozak & Associates Inc. now owns 60 shares of the company’s stock worth $46,000 after purchasing an additional 35 shares in the last quarter. San Luis Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 111.3% in the third quarter. San Luis Wealth Advisors LLC now owns 1,084 shares of the company’s stock valued at $827,000 after buying an additional 571 shares in the last quarter. Raab & Moskowitz Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 23.3% in the third quarter. Raab & Moskowitz Asset Management LLC now owns 2,494 shares of the company’s stock valued at $1,903,000 after buying an additional 471 shares during the period. Apexium Financial LP boosted its stake in shares of Eli Lilly and Company by 1.9% in the third quarter. Apexium Financial LP now owns 1,905 shares of the company’s stock valued at $1,453,000 after buying an additional 35 shares during the period. Finally, Saratoga Research & Investment Management grew its position in Eli Lilly and Company by 65.1% during the third quarter. Saratoga Research & Investment Management now owns 61,459 shares of the company’s stock worth $46,893,000 after buying an additional 24,226 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive pediatric Phase‑3 results for EBGLYSS (lebrikizumab) expand Lilly’s immunology franchise and reduce execution risk on non‑GLP pipeline growth—a clear constructive catalyst for longer‑term revenue diversification. Lilly EBGLYSS Phase 3 Pediatric Results
• Positive Sentiment: Several Wall Street firms remain bullish—some raising targets and highlighting Zepbound/Mounjaro momentum and distribution initiatives (e.g., Employer Connect)—which supports medium‑term sales and margin expectations. Wall Street Firms Turn Bullish on Eli Lilly
• Neutral Sentiment: Disclosure that a member of Congress purchased LLY shares is a data point that can increase watchlist activity but is not a fresh fundamental catalyst. Members of Congress Bought These 5 Stocks—Should You?
• Negative Sentiment: HSBC downgraded LLY to “reduce” (cutting its price target to $850) citing pricing pressure, rising competition, and what it sees as overstated obesity‑market growth—this downgrade triggered selling and repricing of growth expectations. Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations
• Negative Sentiment: Competitive threats intensified after reports of a new GLP‑1 oral pill showing strong weight‑loss data and commentary about Novo Nordisk rivalry; investors are re‑assessing Lilly’s pricing power and market share durability. Structure Weight‑Loss Pill Results Rival Novo, Lilly Treatments
• Negative Sentiment: Market writeups highlight valuation risk: with high multiples already priced for continued GLP‑1 growth, any downgrade or slower uptake triggers outsized downside as investors rotate away from stretched growth names. Why Eli Lilly Stock Just Dropped

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Daiwa Securities Group boosted their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Price Performance

LLY opened at $931.03 on Wednesday. The firm has a 50-day moving average price of $1,033.54 and a 200-day moving average price of $955.52. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $879.65 billion, a price-to-earnings ratio of 40.57, a PEG ratio of 1.15 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.